140 related articles for article (PubMed ID: 31868861)
41. Enzyme replacement therapy with agalsidase alfa in pregnant women with Fabry disease.
Kalkum G; Macchiella D; Reinke J; Kölbl H; Beck M
Eur J Obstet Gynecol Reprod Biol; 2009 May; 144(1):92-3. PubMed ID: 19233535
[No Abstract] [Full Text] [Related]
42. Differences in cleavage of globotriaosylceramide and its derivatives accumulated in organs of young Fabry mice following enzyme replacement therapy.
Kodama T; Tsukimura T; Kawashima I; Sato A; Sakuraba H; Togawa T
Mol Genet Metab; 2017; 120(1-2):116-120. PubMed ID: 27756537
[TBL] [Abstract][Full Text] [Related]
43. Of the importance of the clinical phenotypes in the interpretation of the studies dealing with Fabry disease.
Mauhin W; Lidove O; Benveniste O
Orphanet J Rare Dis; 2019 Jan; 14(1):4. PubMed ID: 30616652
[TBL] [Abstract][Full Text] [Related]
44. Petechial-like lesions, eye abnormalities, and albuminuria in a young boy.
Roganović J
Pediatr Dermatol; 2011; 28(6):727-728. PubMed ID: 22082470
[No Abstract] [Full Text] [Related]
45. Urinary Mulberry Cells as a Biomarker of the Efficacy of Enzyme Replacement Therapy for Fabry Disease.
Aoyama Y; Ushio Y; Yokoyama T; Taneda S; Makabe S; Nishida M; Manabe S; Sato M; Kataoka H; Tsuchiya K; Nitta K; Mochizuki T
Intern Med; 2020; 59(7):971-976. PubMed ID: 32238663
[TBL] [Abstract][Full Text] [Related]
46. Do we need more intensive enzyme replacement therapy for Anderson-Fabry disease?
Basic-Jukic N; Kes P; Mokos I; Coric M
Med Hypotheses; 2009 Apr; 72(4):476-7. PubMed ID: 19124204
[No Abstract] [Full Text] [Related]
47. Electron-microscopy of cherry haemangioma in the early diagnosis of Fabry disease.
Tokuriki A; Kiyohara T; Kumakiri M
Acta Derm Venereol; 2013 Jul; 93(4):471-2. PubMed ID: 23138542
[No Abstract] [Full Text] [Related]
48. Adaptive pathway development for Fabry disease: a clinical approach.
Schuller Y; Arends M; Körver S; Langeveld M; Hollak CEM
Drug Discov Today; 2018 Jun; 23(6):1251-1257. PubMed ID: 29455022
[TBL] [Abstract][Full Text] [Related]
49. Enzyme replacement therapy stabilizes obstructive pulmonary Fabry disease associated with respiratory globotriaosylceramide storage.
Wang RY; Abe JT; Cohen AH; Wilcox WR
J Inherit Metab Dis; 2008 Dec; 31 Suppl 2():S369-74. PubMed ID: 18937048
[TBL] [Abstract][Full Text] [Related]
50. Enzyme replacement therapy improves cardiovascular responses to orthostatic challenge in Fabry patients.
Hilz MJ; Marthol H; Schwab S; Kolodny EH; Brys M; Stemper B
J Hypertens; 2010 Jul; 28(7):1438-48. PubMed ID: 20125036
[TBL] [Abstract][Full Text] [Related]
51. Enzyme Replacement Therapy Clears Gb3 Deposits from a Podocyte Cell Culture Model of Fabry Disease but Fails to Restore Altered Cellular Signaling.
Braun F; Blomberg L; Brodesser S; Liebau MC; Schermer B; Benzing T; Kurschat CE
Cell Physiol Biochem; 2019; 52(5):1139-1150. PubMed ID: 30990584
[TBL] [Abstract][Full Text] [Related]
52. Agalsidase alfa: specific treatment for Fabry disease.
Mehta A
Hosp Med; 2002 Jun; 63(6):347-50. PubMed ID: 12096664
[TBL] [Abstract][Full Text] [Related]
53. Case report of concurrent Fabry disease and amyotrophic lateral sclerosis supports a common pathway of pathogenesis.
Beer AM; Cooper-Knock J; Fletcher S; Brown-Wright SH; Nandakumar TP; Shaw PJ
Amyotroph Lateral Scler Frontotemporal Degener; 2016; 17(7-8):614-616. PubMed ID: 27094629
[No Abstract] [Full Text] [Related]
54. The management and treatment of children with Fabry disease: A United States-based perspective.
Hopkin RJ; Jefferies JL; Laney DA; Lawson VH; Mauer M; Taylor MR; Wilcox WR;
Mol Genet Metab; 2016 Feb; 117(2):104-13. PubMed ID: 26546059
[TBL] [Abstract][Full Text] [Related]
55. Fabry disease.
Thomas AS; Hughes DA
Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():88-101. PubMed ID: 25345090
[TBL] [Abstract][Full Text] [Related]
56. Low-dose agalsidase beta treatment in male pediatric patients with Fabry disease: A 5-year randomized controlled trial.
Ramaswami U; Bichet DG; Clarke LA; Dostalova G; Fainboim A; Fellgiebel A; Forcelini CM; An Haack K; Hopkin RJ; Mauer M; Najafian B; Scott CR; Shankar SP; Thurberg BL; Tøndel C; Tylki-Szymanska A; Bénichou B; Wijburg FA
Mol Genet Metab; 2019 May; 127(1):86-94. PubMed ID: 30987917
[TBL] [Abstract][Full Text] [Related]
57. Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults.
Ortiz A; Oliveira JP; Wanner C; Brenner BM; Waldek S; Warnock DG
Nat Clin Pract Nephrol; 2008 Jun; 4(6):327-36. PubMed ID: 18431378
[TBL] [Abstract][Full Text] [Related]
58. Agalsidase alfa: a review of its use in the management of Fabry disease.
Keating GM
BioDrugs; 2012 Oct; 26(5):335-54. PubMed ID: 22946754
[TBL] [Abstract][Full Text] [Related]
59. An asymptomatic heterozygous female with fabry disease: implications for enzyme replacement therapy.
Inagaki S; Migita M; Hayakawa M; Fujita A; Yoshida J; Ishizaki M; Kotani M; Sakuraba H; Shimada T; Murakami M; Fukunaga Y
J Nippon Med Sch; 2005 Dec; 72(6):387-90. PubMed ID: 16415520
[TBL] [Abstract][Full Text] [Related]
60. [Fabry's disease. An orphan disease that has found a solution: enzymatic replacement with alpha-galactosidase].
Selgas R; García de Lorenzo A; Valdés F; Beck M
Nefrologia; 2001; 21(5):443-7. PubMed ID: 11795012
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
